Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 5
- Registration Number
- NCT00475657
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vigo, Spain
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT00461786
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00456261
- Locations
- 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2009-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT00447421
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT00447057
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00434174
- Locations
- 🇩🇪
Novartis Investigative Site, Koeln, Germany
Pemetrexed in Patients With Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2009-02-16
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 54
- Registration Number
- NCT00427466
- Locations
- 🇩🇪
Medical Center II, University of Tuebingen, Tuebingen, Germany
Pemetrexed in Patients With Advanced Neuroendocrine Tumors
- Conditions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00424723
- Locations
- 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 15
- Registration Number
- NCT00424242
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 698
- Registration Number
- NCT00418886
- Locations
- 🇻🇪
Research Site, Valencia, Venezuela
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.